[Isomeride and treatment of overweight].

Abstract

Controlled European studies of 1 315 patients in medium (3 month) and long term (6 month, 1 year) trials have shown the efficacy and safety of Isomeride in the treatment of overweight. Three month studies of Isomeride plus diet versus placebo plus diet have shown an average weight loss of 3 kilograms in the first month and 7 kilograms after 3 months treatment in the Isomeride group. The difference with placebo was significant in the first month and increased in the following months. Drop out was similar in both groups. The safety of Isomeride made possible long term treatment of particularly severe refractory cases of overweight. A 6 month English trial confirmed these results and a research programme is underway to assess the value of 1 year and more therapy with Isomeride.

• Authors: J P Louvet
• Journal: Annales de medecine interne (Ann Med Interne (Paris)) Vol. 140 Suppl 1 Pg. 17-21 ( 1989) ISSN: 0003-410X [Print] France
• Vernacular Title: Isoméride et traitement des surcharges pondérales.
• PMID: 2672936 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Fenfluramine

Topics

• Double-Blind Method
• Europe
• Fenfluramine (therapeutic use)
• Humans
• International Cooperation
• Multicenter Studies as Topic
• Obesity (drug therapy)
• Random Allocation
• Time Factors